Navigation Links
Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Society's 29th Annual Meeting
Date:9/10/2007

WEST BRIDGEWATER, Mass., Sept. 10 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that data highlighting the advantages of pressure cycling technology (PCT) in studies to (1) better understand the events surrounding stroke, (2) detect biomarkers of colon cancer, and (3) detect proteins associated with embryo viability are to be presented this week in three presentations at the 29th Annual Meeting of the British Mass Spectrometry Society (BMSS). The data were generated by scientists at The New York University (NYU) School of Medicine and the Brooklyn Hospital Center. The presentations will be delivered by Dr. Paul Pevsner, M.D. of the NYU School of Medicine.

Approximately three hundred scientists from around the world are expected to attend the BMSS meeting, where mass spectrometry-related data generated in many key areas of human, animal, and plant research will be showcased. The meeting is being held at the Heriot-Watt University in Edinburgh Scotland.

Dr. Paul H. Pevsner, senior author of the research studies and a scientific investigator at the NYU School of Medicine, said: "Our research program is focused in three areas. First, we are investigating the cascade of events that occurs immediately following a stroke, in an effort to develop successful post-stroke therapeutics. Second, we are attempting to discover new biomarkers of colon cancer, in an effort to develop better surgical aids and diagnostics. Third, we are trying to identify proteins associated with embryo viability from growth media fluid, in an effort to develop better in- vitro fertilization techniques."

Dr. Pevsner continued: "In all cases, we were extremely pleased that PCT could successfully extract the bio-materials of interest, and with a level of speed, reproducibility, and ease-of-use that we have here-to-fore been unable to achieve with any existing extraction method tried. We believe that PCT was essential to our ability to generate the data that we are presenting at the BMSS meeting, and we have therefore made PCT our sample preparation method of choice going forward."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the use of the PCT SPS by the NYU School of Medicine and the Brooklyn Hospital Center, the results of their studies to be presented at the British Mass Spectrometry Society's 29th Annual Meeting, and the advantages of PCT over other sample preparation methods. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT Sample Preparation System; the possibility that other laboratories may be unable to duplicate the results generated by Dr. Pevsner and his colleagues; the possibility that the data generated may not be beneficial in the development of new therapeutics and diagnostics for stroke, colon cancer, and embryo viability; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO

Edward H. Myles, Senior Vice President of Finance & CFO

Pressure BioSciences, Inc.

(508) 580-1818 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The TripleMaster PCR System for three different amplifications
2. Cloning Based on Efficient Three-Fragment Assembly DNA Ligation
3. Three Micron TSK-GEL ODS-100V Columns for High Throughput LCMS
4. Three finalists named for UW-Madison CIO
5. Three state businesses receive technology grants
6. Leading cancer institute to install three TomoTherapy systems
7. Waukesha considers wireless bids from three firms
8. Computerworld top 100 includes three Wisconsin CIOs
9. 30 days to success: Three simple steps to create your own international startup
10. Three firms get state tech development grants
11. Three more Wisconsin firms to present at venture forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic Information for ... Discovery --> --> The ... sequence 100,000 individuals. It is intended to initially include populations ... North and East Asian countries. --> ... focus on creating phased reference genomes for all major Asian ...
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Spectra BioPharma ... Organization (CSO) that provides biopharma companies the experience, ... implement and deploy outsourced sales teams. Created in ... team addresses both the strategic and tactical needs ... innovative sales solutions through both personal and non-personal ...
(Date:2/11/2016)... 11, 2016   BioInformant announces the February ... Research Products, Opportunities, Tools, and Technologies – Market Size, ... The first and ... cell industry, BioInformant has more than a decade of ... market, by stem cell type. This powerful 175 page ...
(Date:2/10/2016)... 2016 Early-career researchers from ... , Uganda and Yemen ... and nutrition   Indonesia , Nepal ... and Yemen are being honored for their accomplishments ... also celebrated for mentoring young women scientists who are pursuing careers in ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> ... Fingerprint Identification System Market by Component (Hardware and Software), ... Finance, Government, Healthcare, and Transportation) and Geography - Global ... expected to be worth USD 8.49 Billion by 2020 ... 2020. The transformation and technology evolution from the manual ...
(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
Breaking Biology News(10 mins):